肿瘤患者抗凝用药审方规则优化的药学实践  

Pharmaceutical practice of optimization of anticoagulants prescription review rules for cancer patients

作　　者：戎佩佩[1] 孙璇[1] 王莹颖[1] RONG Peipei;SUN Xuan;WANG Yingying(Renmin Hospital of Wuhan University,Wuhan,430060,Hubei,China)

机构地区：[1]武汉大学人民医院,湖北武汉430060

出　　处：《肿瘤药学》2023年第4期498-501,共4页Anti-Tumor Pharmacy

摘　　要：目的临床药师通过对肿瘤患者抗凝用药的临床问题进行文献回顾和规则优化,以提高审方系统的敏感性和特异性。方法临床药师定期对警示规则的触发原因进行基于文献的分析和梳理,并基于指南与循证证据优化警示内容。结果对前置审方系统的规则优化可提高医师对警示信息的接受度。结论临床药师可通过优化前置审方规则提高合理用药水平。Objective To improve the sensitivity and specificity of prescription review system by reviewing the literature and optimizing the rules of anticoagulant drugs used in cancer patients.Methods Clinical pharmacists regularly analyze and comb the trigger reasons of warning rules based on literature,and optimize the warning content based on guidelines and evidence-based evidence.Results The optimization on the rules of prescription review system can improve the doctors'acceptance of warning information.Conclusion Clinical pharmacists can improve the level of rational drug use by optimizing the rules of prescription review system.

关 键 词：肿瘤患者 抗凝药物 药学实践 

分 类 号：R973.2[医药卫生—药品]